Case study: a randomized clinical trial in colorectal cancer
death
DISEASE PROGRESSION
Here, this proposed methodology is illustrated using data on the panitumumab colorectal cancer clinical trialThe endpoint considered here was the time from entry to the study until death, following disease progression or death without disease progression. Due to noncompliance in this patient’s population, this study developed new method for estimating the treatment effect in the presence of a competing risk.Due to lack of access to this trial, a Monte Carlo simulation study was conducted to generate data set. The median time to disease progression, time to death and time to death for switching patients was 53, 190 and 49 days, respectively. The survival time was generated for these endpoints from the exponential distribution with parameters log(2)/53, log(2)/190 and log(2)/49, respectively. The results showed that for the proposed method, the HRs for death following disease progression and death without disease progression were 